PersonalisPSNL
PSNL
About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Employees: 229
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
343% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
89% more capital invested
Capital invested by funds: $158M [Q3] → $298M (+$141M) [Q4]
28% more funds holding
Funds holding: 83 [Q3] → 106 (+23) [Q4]
17.54% more ownership
Funds ownership: 55.11% [Q3] → 72.65% (+17.54%) [Q4]
6% less call options, than puts
Call options by funds: $482K | Put options by funds: $511K
31% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 35
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
85%
upside
Avg. target
$7.67
103%
upside
High target
$8
112%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Mike Matson 36% 1-year accuracy 44 / 121 met price target | 85%upside $7 | Buy Reiterated | 10 Apr 2025 |
Craig-Hallum John Wilkin 33% 1-year accuracy 1 / 3 met price target | 112%upside $8 | Buy Initiated | 17 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 192 met price target | 112%upside $8 | Buy Reiterated | 28 Feb 2025 |
Financial journalist opinion
Based on 4 articles about PSNL published over the past 30 days
Neutral
Business Wire
2 days ago
Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing strong performance of its ultra-sensitive NeXT Personal assay in detecting early signs of residual or recurrent colorectal cancer (CRC). The study, led by Dr. Jonathan Loree's team at BC Cancer in Vancouver, Canada, utilized NeXT Personal to look for small traces of circulating tumor DNA (ctDNA) in bloo.
Neutral
Business Wire
1 week ago
Personalis to Announce First Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or.
Neutral
Business Wire
1 week ago
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois. “Our collaborators are excited to present new data, including.
Positive
Investors Business Daily
1 week ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Neutral
Business Wire
1 month ago
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the.
Neutral
Business Wire
1 month ago
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors highlight advancements in breast cancer residual disease (MRD) and recurrence detection using NeXT Personal®, an ult.
Neutral
Seeking Alpha
2 months ago
Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and welcome to the Personalis Fourth Quarter 2024 Earnings Conference Call.
Negative
Zacks Investment Research
2 months ago
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.46 per share a year ago.
Neutral
Business Wire
2 months ago
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024.
Positive
Seeking Alpha
2 months ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Charts implemented using Lightweight Charts™